Most cholesterol drugs, statins included, work by chasing a moving target: they block an enzyme or receptor every day, and the moment you stop taking the pill, the target starts working again. CTX310, from CRISPR Therapeutics, does something structurally different. In a Phase 1 trial reported this week, a single infusion cut LDL cholesterol and triglycerides by 52% in patients with treatment-resistant lipid disorders, by editing the ANGPTL3 gene in liver cells so it can no longer make the protein at all. ANGPTL3 normally holds back two enzymes that clear fat from the blood; silence the gene and those enzymes run unopposed, pulling triglyceride-rich particles out of circulation. The edit happens once, in the DNA itself, not in a protein the drug has to keep suppressing.

The mechanism is a base edit delivered by lipid nanoparticle, the same delivery vehicle as an mRNA vaccine, but here it carries editing machinery into liver cells rather than a vaccine antigen. It lands on a shortlist of gene-silencing cholesterol approaches now in human trials, alongside RNA interference drugs like inclisiran that suppress the same pathway without touching DNA. This is a Phase 1 trial: it establishes that a single edit lowers lipids and, so far, holds, but Phase 1 in the US is built to check safety and dosing in a small group, not to prove it prevents heart attacks. The next gate is whether CRISPR Therapeutics moves CTX310 into a larger Phase 2 trial with a defined cardiovascular endpoint, and how long the reduction lasts before the company needs to report a durability readout beyond the current data.